Opko Health (NASDAQ: OPK) — Perfil da empresa, notícias e dados financeiros
Opko Health is a diversified healthcare company developing pharmaceutical products and diagnostics across various therapeutic areas.

Opko Health
Opko Health (NASDAQ:OPK) is a diversified healthcare company engaged in the discovery, development, and commercialization of pharmaceutical products, diagnostics, and vaccines. The company's operations span across several therapeutic areas, including oncology, rare diseases, and infectious diseases, aiming to address unmet medical needs. Opko Health is actively involved in both in-house research and development projects and strategic collaborations with other industry players to leverage its proprietary technologies. Key objectives for Opko include advancing its pipeline of innovative products to market, expanding its diagnostic services, and continuing to pursue strategic acquisitions that complement its existing portfolio. With a focus on improving patient care and outcomes, Opko Health strives to stay at the forefront of medical innovation.
Resumo
Operações
Produtos e/ou serviços de Opko Health
- Rayaldee, a treatment for secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease and vitamin D insufficiency.
- 4Kscore, a blood test for assessing the risk of aggressive prostate cancer.
- BioReference Laboratories, offering extensive laboratory testing services.
- Pharmadiagnostics, a bioresearch products division providing various diagnostic and therapeutic products.
- Somatrogon, a once-weekly long-acting human growth hormone (hGH) being developed for the treatment of pediatric growth hormone deficiency.
equipe executiva do Opko Health
- Phillip FrostChairman of the Board & CEO
- Jane H. HsiaoVice Chairman of the Board & Chief Technical Officer
- Elias Adam ZerhouniPresident & Vice Chairman of the Board
- Adam E. LogalSenior VP, CFO, Chief Accounting Officer & Treasurer
- Steven D. RubinExecutive VP of Administration & Director
- Akhtar AshfaqSenior Vice President of Clinical Research & Development and Medical Affairs - Opko Renal
- Gary J. NabelChief Innovation Officer & Director
- Giovanni AbbadessaChief Medical Officer of ModeX
- John R. MascolaChief Scientific Officer of ModeX
- Gene YauHead of Business Development
Principais indicadores financeiros
Resultados divulgados pela Opko Health, em USD.
- Cap. de mercado
- 1,2 bi
- Receita (TTM)
- 587,9 mi
- P/L
- —
- LPA (diluído, TTM)
- -0.1
- Dividend yield
- —
- Margem de lucro
- -12.4%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 606,9 mi | -219 mi | -225,7 mi | |
| 713,1 mi | -152,1 mi | -53,2 mi | |
| 863,5 mi | -157 mi | -188,9 mi | |
| 1 bi | -226,3 mi | -328,4 mi |